Avoro Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,462,500
| Closed | -$96.1M | – | 34 |
|
|
2024
Q4 | $96.1M | Sell |
1,462,500
-575,515
| -28% | -$38.5M | 1.36% | 19 |
|
|
2024
Q3 | $143M | Sell |
2,038,015
-2,519,401
| -55% | -$211M | 2.09% | 15 |
|
|
2024
Q2 | $375M | Buy |
4,557,416
+192,416
| +4% | +$16M | 5% | 8 |
|
|
2024
Q1 | $381M | Buy |
4,365,000
+65,000
| +2% | +$5.82M | 4.45% | 9 |
|
|
2023
Q4 | $415M | Buy |
4,300,000
+450,000
| +12% | +$39.8M | 5.73% | 7 |
|
|
2023
Q3 | $341M | Sell |
3,850,000
-150,000
| -4% | -$13.3M | 5.31% | 8 |
|
|
2023
Q2 | $347M | Buy |
4,000,000
+55,000
| +1% | +$5.18M | 4.7% | 7 |
|
|
2023
Q1 | $384M | Buy |
3,945,000
+389,445
| +11% | +$40.4M | 5.69% | 7 |
|
|
2022
Q4 | $368M | Hold |
3,555,555
| – | – | 5.5% | 8 |
|
|
2022
Q3 | $301M | Buy |
3,555,555
+271,555
| +8% | +$24.2M | 5.57% | 7 |
|
|
2022
Q2 | $272M | Buy |
3,284,000
+249,000
| +8% | +$19.8M | 5.38% | 7 |
|
|
2022
Q1 | $234M | Buy |
3,035,000
+235,000
| +8% | +$19.7M | 4.27% | 9 |
|
|
2021
Q4 | $247M | Buy |
2,800,000
+925,000
| +49% | +$76.3M | 4.21% | 8 |
|
|
2021
Q3 | $145M | Buy |
1,875,000
+225,000
| +14% | +$17.8M | 2.28% | 13 |
|
|
2021
Q2 | $138M | Hold |
1,650,000
| – | – | 2.4% | 13 |
|
|
2021
Q1 | $125M | Hold |
1,650,000
| – | – | 2.15% | 12 |
|
|
2020
Q4 | $145M | Sell |
1,650,000
-100,000
| -6% | -$7.93M | 2.49% | 12 |
|
|
2020
Q3 | $133M | Sell |
1,750,000
-100,000
| -5% | -$10.1M | 1.89% | 12 |
|
|
2020
Q2 | $228M | Sell |
1,850,000
-80,000
| -4% | -$7.95M | 4.51% | 7 |
|
|
2020
Q1 | $163M | Sell |
1,930,000
-70,000
| -4% | -$6.03M | 5.5% | 5 |
|
|
2019
Q4 | $169M | Sell |
2,000,000
-437,100
| -18% | -$33M | 4.97% | 7 |
|
|
2019
Q3 | $164M | Buy |
2,437,100
+322,100
| +15% | +$24.8M | 6.85% | 5 |
|
|
2019
Q2 | $181M | Buy |
2,115,000
+995,000
| +89% | +$85.1M | 6.26% | 6 |
|
|
2019
Q1 | $99.5M | Sell |
1,120,000
-240,000
| -18% | -$22.2M | 4.3% | 11 |
|
|
2018
Q4 | $116M | Sell |
1,360,000
-8,103
| -0.6% | -$771K | 6.92% | 5 |
|
|
2018
Q3 | $133M | Sell |
1,368,103
-254,667
| -16% | -$25.4M | 6.09% | 5 |
|
|
2018
Q2 | $153M | Sell |
1,622,770
-88,225
| -5% | -$7.73M | 5.88% | 3 |
|
|
2018
Q1 | $139M | Buy |
1,710,995
+521,471
| +44% | +$44.8M | 6.62% | 3 |
|
|
2017
Q4 | $106M | Buy |
1,189,524
+591,552
| +99% | +$51.4M | 6.88% | 2 |
|
|
2017
Q3 | $55.7M | Buy |
597,972
+97,183
| +19% | +$8.59M | 4.32% | 8 |
|
|
2017
Q2 | $45.5M | Sell |
500,789
-89,211
| -15% | -$8.12M | 5.74% | 5 |
|
|
2017
Q1 | $51.8M | Buy |
590,000
+190,000
| +48% | +$16.9M | 6.62% | 5 |
|
|
2016
Q4 | $33.1M | Sell |
400,000
-19,712
| -5% | -$1.7M | 6.69% | 3 |
|
|
2016
Q3 | $38.8M | Sell |
419,712
-13,260
| -3% | -$1.25M | 6.81% | 2 |
|
|
2016
Q2 | $33.7M | Buy |
432,972
+155,700
| +56% | +$13.2M | 7.49% | 4 |
|
|
2016
Q1 | $22.9M | Buy |
+277,272
| New | +$22.6M | 7.98% | 3 |
|
Other funds holding BMRN
EIM
Avoro Capital Advisors's BMRN Position: Q1 2025 in Review
Avoro Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 1,462,500 shares — an estimated $96.1M sold.
Avoro Capital Advisors first reported a position in BMRN in Q1 2016 and held it in 36 quarters. The position peaked at $415M in Q4 2023. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.
- Avoro Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Avoro Capital Advisors sold 1,462,500 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $96.1M.
- Avoro Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 36 quarters.
- Avoro Capital Advisors's BioMarin Pharmaceuticals position peaked at $415M in Q4 2023.
- 584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.
Based on Avoro Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.